Kymera director awarded 6,068 stock options

Kymera Therapeutics director Elena Ridloff reported a new equity award.

Rhea-AI Filing Summary

Kymera Therapeutics director Elena Ridloff reported a new equity award. She received a stock option covering 6,068 shares of common stock at an exercise price of 99.87 per share, expiring on June 23, 2036. The option vests in full on the earlier of June 24, 2027 or the next annual stockholder meeting. This is a compensation-related grant, not an open-market purchase or sale, and results in Ridloff holding 6,068 derivative securities directly.

Insider Trade Summary

Grant/Award: 6,068 shares

Grant/Award 1 txn

Insider Ridloff Elena

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,068	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 6,068 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Key Figures

Option grant size: 6,068 shares Exercise price: 99.87 per share Expiration date: June 23, 2036 +3 more

6 metrics

Option grant size 6,068 shares Stock option covering Kymera common stock

Exercise price 99.87 per share Conversion or exercise price of the option

Expiration date June 23, 2036 Stock option term end date

Underlying shares 6,068 shares Common stock underlying the option

Post-transaction derivative holdings 6,068 derivative securities Total options held after grant

Vesting trigger date June 24, 2027 Latest date for full vesting, absent earlier annual meeting

Key Terms

Stock Option (Right to Buy), grant/award acquisition, Common Stock, exercise price, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 99.8700"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"shares underlying this stock option shall vest in full"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kymera Therapeutics (KYMR) disclose for Elena Ridloff?

Kymera Therapeutics disclosed that director Elena Ridloff received a grant of stock options for 6,068 shares of common stock. The option is a compensation-related award, not an open-market trade, and represents her current reported derivative holdings following the transaction.

What are the key terms of Elena Ridloff’s new Kymera (KYMR) stock option grant?

The grant covers 6,068 underlying shares of Kymera common stock with an exercise price of 99.87 per share. The option expires on June 23, 2036 and vests in full upon a specified future date tied to service as a director.

When do Elena Ridloff’s Kymera stock options vest according to the Form 4?

The stock options vest in full on the earlier of June 24, 2027 or the date of Kymera Therapeutics’ next annual meeting of stockholders. This time-based vesting means full exercisability depends on continued board service until one of those milestones.

Did Elena Ridloff buy or sell Kymera (KYMR) shares in this Form 4 filing?

The filing shows no open-market buying or selling of Kymera shares. Instead, it reports a grant of stock options as compensation, classified as an acquisition of a derivative security rather than a purchase or sale of common stock in the market.

How many Kymera shares could be acquired under Elena Ridloff’s new option grant?

The option grant is exercisable for 6,068 shares of Kymera Therapeutics common stock. Once the award vests and if exercised at the stated exercise price, it would convert into that same number of common shares, increasing her direct equity exposure.

What is the expiration date of Elena Ridloff’s Kymera stock options?

The options granted to Elena Ridloff expire on June 23, 2036. After that date, any unexercised portion of the 6,068-share award would lapse, so the long-dated term provides a substantial window to potentially exercise after vesting conditions are met.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/25/2026 - 06:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ridloff Elena

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$99.87	06/24/2026		A		6,068		(1)	06/23/2036	Common Stock	6,068	$0	6,068	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)